Literature DB >> 16061390

Angiotensin receptors: a new role in cancer?

Frédérique Deshayes1, Clara Nahmias.   

Abstract

There is increasing evidence that Angiotensin II (AngII), a major regulator of blood pressure and cardiovascular homeostasis, is involved in the regulation of cell proliferation, angiogenesis, inflammation and tissue remodeling, which suggests that this peptide might also play a role in cancer. This review focuses on the expression and function of Angiotensin I-converting enzyme (ACE) and AngII receptors in various aspects of cancer. Recent experimental data suggests that ACE inhibitors and AngII type 1 receptor (AT1R) antagonists have beneficial effects on tumor progression, vascularization and metastasis, and that the AngII type 2 receptor (AT2R) subtype has a potential role in cancer. An overview of the major intracellular signaling pathways associated with AT1R and AT2R activation in cancer cells, as well as in endothelial and inflammatory cells, is presented here.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061390     DOI: 10.1016/j.tem.2005.07.009

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  131 in total

Review 1.  Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about?

Authors:  Vadim Tchaikovski; Gregory Y H Lip
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 2.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

3.  Is there a link between angiotensin receptor blockers and cancer?

Authors:  Frank Enseleit; Frank Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 4.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

5.  Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

Authors:  Rana R McKay; Gustavo E Rodriguez; Xun Lin; Marina D Kaymakcalan; Ole-Petter R Hamnvik; Venkata S Sabbisetti; Rupal S Bhatt; Ronit Simantov; Toni K Choueiri
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

6.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Authors:  Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

7.  A role for the renin-angiotensin system in hematopoiesis.

Authors:  Tea Soon Park; Elias T Zambidis
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

Review 8.  Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer.

Authors:  Nijiro Nohata; Yusuke Goto; J Silvio Gutkind
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

9.  Angiotensin II induces DNA damage via AT1 receptor and NADPH oxidase isoform Nox4.

Authors:  Gholamreza Fazeli; Helga Stopper; Reinhard Schinzel; Chih-Wen Ni; Hanjoong Jo; Nicole Schupp
Journal:  Mutagenesis       Date:  2012-07-27       Impact factor: 3.000

10.  Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil.

Authors:  Peter Hallersund; Herbert F Helander; Anna Casselbrant; Anders Edebo; Lars Fändriks; Anders Elfvin
Journal:  BMC Gastroenterol       Date:  2010-01-14       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.